JPRN-UMIN000021298尚未招募2 期
A phase 2 trial of GN (gemcitabine + nedaplatin) therapy for advanced urothelial cancer patients with pre-treatment of cisplatin or carboplatin. - GN for UC with pre-platinum-based-drug-treatment
Yamagata University, Department of Urology0 个研究点目标入组 62 人开始时间: 2016年3月4日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 62
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Patients with sever bone marrow suppression 2) Patinets with interstitial pneumonitis or lung fibrosis 3) Patients with prior radiotherapy for chest 4) Patients with hypersensitivity reaction for the protocol drugs 5) Patients without histological diagnosis 6) Patients with prior therapy used nedaplatin 7) Patients without lesions assessed by RECISTv1.1
研究者
相似试验
已完成
不适用
PhaseII trial of Gemcitabine(G)and Platinam-doublet plus continuous maintenance Gemcitabine in untreated stage three/four squamous non-small cell lung cancer(NSCLC)on-small cell lung cancerJPRN-UMIN000011794Hiroshima University Hospital33
进行中（未招募）
1 期
_Metastatic collecting duct carcinomaMedDRA version: 17.1 Level: LLT Classification code 10073252 Term: Carcinoma of the collecting ducts of Bellini System Organ Class: 100000004864EUCTR2013-001179-19-FRICANCER41
进行中（未招募）
1 期
Randomized phase 2 study of gemcitabine/cisplatin with or without SAR240550(BSI-201), a PARP1 inhibitor, in patients with stage IV non-small cell lung canceron-small cell lung cancer stage IV.MedDRA version: 12.1Level: LLTClassification code 10029522Term: Non-small cell lung cancer stage IVEUCTR2009-017270-21-FRsanofi-aventis recherche & développement105
进行中（未招募）
不适用
Randomized phase 2 study of gemcitabine/cisplatin with or without SAR240550(BSI-201), a PARP1 inhibitor, in patients with stage IV non-small cell lung canceron-small cell lung cancer stage IV.MedDRA version: 12.1Level: LLTClassification code 10029522Term: Non-small cell lung cancer stage IVEUCTR2009-017270-21-DEsanofi-aventis recherche & développement
进行中（未招募）
不适用
Randomized phase 2 study of gemcitabine/cisplatin with or without SAR240550 (BSI-201), a PARP1 inhibitor, in patients with stage IV non-small cell lung canceron-small cell lung cancer stage IVMedDRA version: 14.0Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-017270-21-ITsanofi-aventis recherche & de'veloppement105